Industrial Research and Development of a monoclonal antibody with the codename DM-02 as a biological therapy for plasma cell dyscrasias (PCD) within the Modern Regulatory Framework

Region:

Attica

Sector:

Research and Development

Inter-ministerial Decision:

αρ. 86/2023

Implementation Entity:

DEMO A.B.E.E.

Budget:

44.433.967 €

Project Briefing:

Industrial Research and Development of a monoclonal antibody with the codename DM-02 as a biological therapy for plasma cell dyscrasias (PCD) within the Modern Regulatory Framework.

Related files:

General Secretariat

Leadership
Organizational Structure

Press Releases

Press Releases

Links

Ministry of Development
Complaints

Contact

Contact Information

Co-funded by the European Union and Greece